Analysis of individual placements across 43 companies over the past 18 months paints a vivid picture of Japan’s evolving healthcare industry. This comprehensive snapshot illuminates current market demands, strategic shifts, and the enduring appeal of this pivotal Asian market.Rare Diseases…
HOME > REGULATORY
REGULATORY
- LDP Tax Panel OKs Refit of R&D Tax Credit System in FY2017
December 7, 2016
- Daratumumab Granted Orphan Drug Status
December 7, 2016
- PM Abe’s Council to Discuss Annual Drug Price Revisions Again on Dec. 7
December 5, 2016
- MHLW OKs Add’l Indications for Opdivo, Other Drugs
December 5, 2016
- Clinical Research Bill Unlikely to Clear Extra Diet
December 5, 2016
- Panel Shelves Decision on Reimbursement Rate for OTC-Switched Rx
December 1, 2016
- LDP Group Submits Resolution Calling for “Drug Pricing Agency”
December 1, 2016
- HIV Combo Pill Prezcobix OK’ed for NHI Price Listing
December 1, 2016
- Industry, Healthcare Provider Reps Oppose “Annual Revisions” as Payers Hold Off Stance: Chuikyo
December 1, 2016
- Chuikyo at Odds over Price Maintenance Premium
December 1, 2016
- Chuikyo to Discuss “Price-Setting Including NHI Price Increases” Using Cost-Effective Assessments
December 1, 2016
- “Outright” or “Partial”? Annual Revision Debate Rekindled in a Rush to Revamp Drug Pricing
November 30, 2016
- MID-NET Working Group Agrees on Flat Access Fees for Drug Makers’ PMS Use
November 30, 2016
- Shiozaki Hints at Possible Drug Price Survey in Different Method
November 30, 2016
- Before Micatrio, Patient Must Take 3 Contained Compounds for at Least 8 Weeks: MHLW
November 29, 2016
- Japan Ophthalmologists Association Calls for Reductions in NHI Prices of High-Cost Drugs
November 29, 2016
- LDP Study Group Kicks Off to Put Brakes on Hasty Push for Biosimilars
November 28, 2016
- Eltrombopag, Nusinersen Designated as Orphan Drugs
November 28, 2016
- MHLW Advisory Panel OKs Biogen’s Tecfidera, Other Drugs
November 28, 2016
- Annual Price Revision Push Gaining Momentum; PM Wants Pricing Revamp Policy by Year-End
November 28, 2016
ページ
The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…